M&A Deal Summary |
|
---|---|
Date | 2022-09-07 |
Target | Ducentis BioTherapeutics |
Sector | Life Science |
Buyer(s) | Arcutis |
Deal Type | Add-on Acquisition |
Deal Value | 16M USD |
Advisor(s) | Goodwin Procter (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 2016 |
Sector | Life Science |
Employees | 296 |
Revenue | 60M USD (2023) |
Arcutis is focused on developing topical medicines for the treatment of skin diseases. The company’s lead program, ARQ-151, is a topical formulation of roflumilast that is currently in Phase 2 studies for the treatment of plaque psoriasis and atopic dermatitis. The company’s second program, ARQ-250, is a topical JAK1-inhibitor in preclinical development for the treatment of various autoimmune diseases affecting the skin. Arcutis was founded in 2016 and is based in Westlake Village, California.
DEAL STATS | # |
---|---|
Overall | 1 of 1 |
Sector (Life Science) | 1 of 1 |
Type (Add-on Acquisition) | 1 of 1 |
Country (United Kingdom) | 1 of 1 |
Year (2022) | 1 of 1 |
Size (of disclosed) | 1 of 1 |